Core Viewpoint - The article discusses a class action lawsuit against Paysafe Limited, highlighting allegations of securities fraud related to undisclosed risks and financial misstatements during a specific period [4]. Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Paysafe securities from March 4, 2025, to November 12, 2025, alleging that the company failed to disclose significant risks associated with a high-risk client [4]. - Allegations include understated credit loss reserves, issues with higher risk Merchant Category Codes, and the likelihood that Paysafe would not meet its financial guidance for fiscal year 2025 [4]. - The lawsuit emphasizes that these undisclosed issues could materially impact the company's revenue growth and overall revenue mix [4]. Group 2: Financial Impact - On November 13, 2025, Paysafe reported third-quarter financial results that missed revenue and EPS estimates, attributing a several-million-dollar write-down to a last-minute client shutdown [5]. - The company's credit loss expense for the three months ended September 30, 2025, was reported at $13,220, primarily due to expected chargebacks related to a specific merchant [5]. - Following the financial report, Paysafe's share price dropped by $2.80, approximately 27.6%, from $10.16 to $7.36 [5].

Core Viewpoint - A class action lawsuit has been filed against Enphase Energy, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from April 22, 2025, to October 28, 2025, seeking damages for misleading statements regarding the company's business and financial prospects [1]. Company Overview - Enphase Energy, Inc. is a global energy technology company founded in March 2006, focusing on solar generation, storage, and communication solutions [1]. - The company partners with solar and battery financing companies to offer third-party ownership arrangements for solar and battery products to homeowners [1]. Financial Context - Enphase reported "safe harbor revenue," defined as sales made to customers planning to install its products over more than a year [1]. - The Residential Clean Energy Credit allowed homeowners to deduct 30% of costs for clean energy property installed at their homes, which was set to terminate on December 31, 2025, instead of December 31, 2032, as originally enacted [1]. Allegations in the Lawsuit - The lawsuit alleges that Enphase made materially false and misleading statements regarding its ability to manage channel inventory and mitigate the effects of the termination of the 25D Credit, leading to an overstatement of its financial and operational prospects [1]. - Specific allegations include that Enphase overstated its ability to manage inventory and its financial outlook, resulting in misleading public statements throughout the Class Period [1]. Stock Market Reaction - Following the announcement of its third-quarter financial results on October 28, 2025, Enphase's stock price fell by $5.56 per share, or 15.15%, closing at $31.14 per share on October 29, 2025, due to concerns over elevated channel inventory and the impact of the 25D Credit expiration on future revenues [1].

Core Viewpoint - A class action lawsuit has been filed against Quantum Biopharma Ltd. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by February 23, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that Quantum and certain officers and/or directors engaged in securities fraud [1]. - Defendants, including CIBC World Markets and Royal Bank of Canada, are accused of placing thousands of spoofed sell orders to create a false impression of Quantum's stock price decline [1]. - These manipulative orders allegedly deceived investors into selling their shares at artificially low prices, allowing the Defendants to purchase shares at depressed levels for profit [1]. Group 2: Legal Representation - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is representing the affected investors [1]. - The firm has a long history of fighting for victims of securities fraud and has recovered numerous multimillion-dollar damages awards [1].

Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for allegedly making false statements and failing to disclose critical information regarding its financial guidance and the impact of strategic actions taken by the company [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased agilon securities between February 26, 2025, and August 4, 2025, alleging that the company issued misleading guidance for 2025 despite being aware of significant industry challenges [4]. - The lawsuit claims that agilon overstated the positive financial impact from its strategic actions aimed at reducing risk [4]. Group 2: Company Events - On August 4, 2025, agilon announced the resignation of its President and CEO, Steven Sell, which was classified as a termination without cause [5]. - The same day, agilon reported its second-quarter results and acknowledged that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [5]. - Following these announcements, agilon's stock price fell by $0.94, or approximately 51.6%, from $1.82 to $0.88 per share [5].

SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors in Klarna Group plc (NYSE: KLAR) of the upcoming February 20, 2026, lead plaintiff deadline in a pending securities class action. The firm is actively investigating the lawsuit’s claims of alleged misstatements in Klarna’s September 2025 Initial Public Offering (IPO) documents. CLICK HERE TO SUBMIT YOUR KLARNA LOSSES Investors who purchased Klarna (KLAR) shares pursuant to the company’s ...

Core Viewpoint - Investors in China Liberal Education Holdings Limited (CLEUF) have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred from alleged fraudulent activities [1] Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that between January 22, 2025, and January 30, 2025, the defendants failed to disclose that CLEU shares were involved in a pump-and-dump scam [1] - It is claimed that the December 2024 Issuance and the Warrant Exchange Agreement were not legitimate transactions, intended to transfer CLEU shares to individuals involved in the scam [1] - The positive statements made by the defendants regarding the company's business and prospects were misleading and lacked a reasonable basis during the relevant period [1] Participation Information - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith before March 31, 2026, to participate in the ongoing lawsuit [1] - Interested parties can reach out via email, phone, or the law firm's website for more information regarding their rights and the class action [1]

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultragenyx investors who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/ultrag ...

Core Points - A class action securities lawsuit has been filed against CoreWeave, Inc. for alleged securities fraud affecting investors between March 28, 2025, and December 15, 2025 [1][2] - The complaint claims that CoreWeave's management overstated the company's ability to meet customer demand and understated risks associated with reliance on a single third-party data center supplier, which could negatively impact revenue [2] - Investors who suffered losses during the specified period have until March 13, 2026, to request to be appointed as lead plaintiff, with no out-of-pocket costs to participate in the lawsuit [3] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Picard Medical, Inc. ("Picard Medical, Inc." or the "Company") (NYSE: PMI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Picard Medical, Inc. investors who were adversely affected by alleged securities fraud between September 2, 2025 and October 31, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra ...

Core Viewpoint - A class action securities lawsuit has been filed against Beyond Meat, Inc. for alleged securities fraud affecting investors between February 27, 2025, and November 11, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding the book value of Beyond Meat's long-lived assets, which exceeded their fair value, indicating a likely need for a material, non-cash impairment charge [2]. - It is alleged that this situation could impair Beyond Meat's ability to file periodic reports with the SEC on time, rendering the defendants' public statements materially false and misleading [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until March 24, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].